The Potential Prognostic Impact of Associated Peritoneal Carcinomatosis in Patients with Stage II and III Epithelial Ovarian Cancer Who Had Upfront Complete Cytoreduction

Mohamed Ibrahim Fahim, Rasha Mahmoud Allam

Tóm tắt

Từ khóa


Tài liệu tham khảo

Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol. 1998;25(3):305–14.

Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29(1):69–73. https://doi.org/10.1053/ejso.2002.1380.

Cavaliere F, Giannarelli D, Valle M, Federici O, Liotta G, Perri P, Di Filippo F, Garofalo A, Ialongo P. Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment. In Vivo. 2009;23(3):441–6.

Uzan J, Bonsang-Kitzis H, Rossi L, Rance B, Bats AS, Gosset M, Deloménie M, Pujade-Lauraine E, Lécuru F, Ngô C. Prognostic impact of initial tumor load and intraperitoneal disease dissemination patterns in patients with advanced ovarian cancer undergoing complete cytoreductive surgery. Eur J Surg Oncol. 2019;45(9):1619–24. https://doi.org/10.1016/j.ejso.2019.04.011.

Sun JH, Ji ZH, Yu Y, Wu HT, Huang CQ, Zhang Q, Yang XJ, Yonemura Y, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat advanced/recurrent epithelial ovarian cancer: results from a retrospective study on prospectively established database. Transl Oncol. 2016;9(2):130–8. https://doi.org/10.1016/j.tranon.2016.02.002.

Gasimli K, Braicu EI, Richter R, Chekerov R, Sehouli J. Prognostic and predictive value of the peritoneal cancer index in primary advanced epithelial ovarian cancer patients after complete cytoreductive surgery: study of tumor bank ovarian cancer. Ann Surg Oncol. 2015;22(8):2729–37. https://doi.org/10.1245/s10434-014-4329-7.

Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E, Soliman AA. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol. 2018;29(4): e47. https://doi.org/10.3802/jgo.2018.29.e47.

Muñoz-Casares FC, Medina-Fernández FJ, Arjona-Sánchez Á, Casado-Adam Á, Sánchez-Hidalgo JM, Rubio MJ, Ortega-Salas R, Muñoz-Villanueva MC, Rufián-Peña S, Briceño FJ. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol. 2016;42(2):224–33. https://doi.org/10.1016/j.ejso.2015.11.006.

Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19(13):4052–8. https://doi.org/10.1245/s10434-012-2510-4.